Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session titled "Bi and Multispecific Biologics" and ...

NDAQ:APVO) Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute ...

Is Aptevo Therapeutics Inc. (APVO) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out. Aptevo Therapeutics Inc. is one of 1011 companies in the ...

and 4-1BBx5T4 bispecific antibody ALG.APV-527 – being co-developed with Aptevo Therapeutics – which is in early clinical development. Last month, Alligator reported updated results from the ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Applied Therapeutics Inc., Treasure Global Inc., Procaps Group SA, Mondee Holdings Inc., and Aptevo Therapeutics Inc. were among the top losers for the market session on Friday, according to ...

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...